Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer (opens in a new tab)
CompletedPhase 2
DurvalumabTremelimumab
Dr. Fariborze B. Barhamand, MD
NPI1093810491
- Medicare services, 2019
- 2,012
- Part D claims, 2019
- 361
- Clinical trials
- 10
- Industry payments
- $77
- Affiliated sites
- 2
- Practice address
- 100 Spalding Dr, Naperville, IL 60540
- Practice phone
- Call (630) 718-2660
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Advocate Medical Group (dreyer) - Naperville (Spalding Dr)
Primary care practice · Naperville, Illinois
Find Dr. Barhamand's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Fariborze B. Barhamand is a hematologist and oncologist in Naperville, Illinois
Dr. Barhamand practices at Advocate Medical Group (dreyer) - Naperville (Spalding Dr) in Naperville, Illinois.
Dr. Barhamand's NPI, 1093810491, was assigned on September 13, 2006. Dr. Barhamand holds Illinois license 036-053994.
NPI and contact details
- NPI
- 1093810491NPI Registry (opens in a new tab)
- NPI enumeration date
- September 13, 2006
- NPI status
- Active
- Practice phone
- (630) 718-2660
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Fariborze B. Barhamand practices at Advocate Medical Group (dreyer) - Naperville (Spalding Dr) in Naperville, Illinois
Dr. Barhamand's primary practice is Advocate Medical Group (dreyer) - Naperville (Spalding Dr), at 100 Spalding Dr, Naperville, IL 60540. The practice phone is (630) 718-2660.
- Advocate Medical Group (dreyer) - Naperville (Spalding Dr)100 Spalding Dr, Naperville, IL 60540Phone(630) 718-2660
Sources: Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Fariborze B. Barhamand is affiliated with 2 sites of care and 1 medical group
Dr. Barhamand's primary practice is Advocate Medical Group (dreyer) - Naperville (Spalding Dr) in Naperville, Illinois. The medical group on file is Dreyer Medical Clinic (Advocate Medical Group). Dmand AI also links Dr. Barhamand to 1 more physician office, named with a free account.
Advocate Medical Group (dreyer) - Naperville (Spalding Dr)Primary
Sources: Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dmand AI tracks the EHR system at Dr. Fariborze B. Barhamand's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Barhamand practices, 2 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Advocate Medical Group (dreyer) - Naperville (Spalding Dr) | Available with a free account |
| +1 more affiliated site | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every site where Dr. Barhamand practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Fariborze B. Barhamand is one of 563 hematologists and oncologists in Illinois
Hematology and oncology is Dr. Barhamand's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Barhamand is licensed in Illinois.
Specialties and state licenses
- Hematology and oncology, IllinoisPrimary
Hematologists and oncologists near Dr. Barhamand
Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.
563hematologists and oncologists in Illinois
2hematologists and oncologists in Naperville
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Fariborze B. Barhamand billed Medicare for 2,012 services in 2019
CMS data shows 2,012 Medicare services from Dr. Barhamand across 12 procedure codes in 2019. Medicare paid $61,412 for them.
Medicare services, 20192,012
Paid by Medicare$61,412
Procedure codes12
Dr. Barhamand's Medicare services by type, 2018 to 2019
- 2018
- 2019
- Lab and pathology
- 2018: 1,8492019: 64765%
- Office and hospital visits
- 2018: 1,7522019: 58467%
- Surgery
- 2018: 1,5362019: 50667%
- Tests and treatments
- 2018: 1,1382019: 27576%
- Drugs given in the office
- 2018: 32,5142019: 0100%
Where Dr. Barhamand's Medicare services took place, 2019
- In an office1,91895%
- In a facility945%
Dr. Barhamand compared with the Illinois median for hematologists and oncologists, 2019
- Dr. Barhamand
- Illinois median
- Medicare services
- 2,012vs 1,05691% above
- Part D claims
- 361vs 32810% above
Medians across 547 hematologists and oncologists in Illinois with Dmand AI profiles that report each measure.
Dr. Barhamand's most billed Medicare procedure codes, 2019
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Barhamand?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Barhamand and other hematologists and oncologists in Illinois.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Fariborze B. Barhamand's patients have a median age of 68
Across all payers, Dmand AI patient panel data puts Dr. Barhamand's median patient age at 68, with 43% women.
Dr. Barhamand's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 68
Patient panel by sex, all payers
- Women43%
- Men43%
Source: Dmand AI Patient Panel Data
Dr. Fariborze B. Barhamand wrote 361 Medicare Part D claims in 2019
In 2019, Dr. Barhamand wrote 361 Medicare Part D claims. They cover 14 drugs, with $601,231 in total drug cost. In 2018, CMS named 1,129 claims across 34 drugs.
Part D claims, 2019361
Drugs named by CMS14
Total drug cost$601,231
Dr. Barhamand's most prescribed drugs by claims, 2019
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2018 to 2019
- 2018
- 2019
- Claims for drugs CMS names
- 2018: 1,1292019: 36168%
Drugs named by CMS: 14 in 2019, 34 in 2018.
Source: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026
For MedTech and pharma teams
Find hematologists and oncologists like Dr. Barhamand by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Fariborze B. Barhamand has worked on 10 clinical trials
Dmand AI links Dr. Barhamand to 10 clinical trials, 6 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Breast Neoplasms, Male. SWOG Cancer Research Network sponsors the most, 5.
Clinical trials with Dr. Barhamand by phase
- NonePhase 1: no trials
- 2Phase 2: 2 trials
- 6Phase 3: 6 trials
- NonePhase 4: no trials
Conditions in Dr. Barhamand's trials
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Bronchogenic
- Breast Neoplasms, Male
- Carcinoma, Intraductal, Noninfiltrating
- Breast Carcinoma In Situ
Investigators on the most trials with Dr. Barhamand
- Jennifer T. Eubanks, MD8 shared trials
- David Kendall Goebel, MD8 shared trials
- Roberto F. Martinez, MD8 shared trials
Recent clinical trials with Dr. Barhamand
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (opens in a new tab)
Active, not recruitingPhase 3
Carcinoma, Non-Small-Cell LungCarcinoma, BronchogenicNivolumab
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (opens in a new tab)
Active, not recruitingPhase 3
IpilimumabNivolumab
Carcinoma, Non-Small-Cell LungCarcinoma, BronchogenicCrizotinib
Sources: ClinicalTrials.gov (National Library of Medicine); and Dmand AI Research Linkage
Dr. Fariborze B. Barhamand received $77 in industry payments from 2016 to 2018
CMS Open Payments shows 4 general payments to Dr. Barhamand from 4 drug and device companies from 2016 to 2018. Food and beverage make up the largest share, 79% of the total. Janssen Pharmaceuticals, Inc paid the most, $24.
General payments to Dr. Barhamand by program year, 2016 to 2018
General payments to Dr. Barhamand by kind, 2016 to 2018
$77in total
- Food and beverage$6179%
- Education$1621%
Companies that paid Dr. Barhamand the most, 2016 to 2018
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. Fariborze B. Barhamand's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation DataDoctors and Clinicians National Downloadable File (CMS) (opens in a new tab) |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDoctors and Clinicians National Downloadable File (CMS) (opens in a new tab) |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel Data |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab) |
| Clinical trials and co-investigators | ClinicalTrials.gov (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Fariborze B. Barhamand
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Fariborze B. Barhamand's NPI number?
Dr. Fariborze B. Barhamand's NPI number is 1093810491. It was assigned on September 13, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. Fariborze B. Barhamand?
Dr. Fariborze B. Barhamand is a hematologist and oncologist in Naperville, Illinois. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).
Where does Dr. Fariborze B. Barhamand practice?
Dr. Barhamand practices at 100 Spalding Dr, Naperville, IL 60540. Dr. Barhamand's primary practice is Advocate Medical Group (dreyer) - Naperville (Spalding Dr) in Naperville, Illinois. Dmand AI also links Dr. Barhamand to 1 physician office.
What is Dr. Fariborze B. Barhamand's office phone number?
The practice phone on file for Dr. Barhamand is (630) 718-2660.
What is Dr. Fariborze B. Barhamand's medical license number?
Dr. Barhamand holds Illinois license 036-053994.
What medical group is Dr. Fariborze B. Barhamand part of?
Dr. Barhamand is linked to Dreyer Medical Clinic (Advocate Medical Group).
Does Dr. Fariborze B. Barhamand accept Medicare?
Yes. CMS data shows Dr. Barhamand billed Medicare for 2,012 services in 2019.
What services does Dr. Fariborze B. Barhamand bill to Medicare?
In 2019, Dr. Barhamand's most billed Medicare services were lab and pathology test (85025), surgery: heart and blood vessels (36415) and office visit, established patient (99214).
What drugs does Dr. Fariborze B. Barhamand prescribe most?
In 2019 Medicare Part D data, Dr. Barhamand's most prescribed drugs by claims were Anastrozole, Warfarin Sodium and Letrozole.
Has Dr. Fariborze B. Barhamand received payments from drug or device companies?
CMS Open Payments shows $77 in general payments to Dr. Barhamand from 4 companies from 2016 to 2018. The largest total came from Janssen Pharmaceuticals, Inc.
How long has Dr. Fariborze B. Barhamand been practicing?
Dr. Barhamand's NPI was assigned in 2006.
Does Dr. Fariborze B. Barhamand do research?
Dr. Barhamand has worked on 10 clinical trials.
Selling to hematology and oncology practices?
See hematologists and oncologists in Illinois by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card